Patient Characteristics
| Characteristic | Data |
|---|---|
| Age (y) | |
| Mean | 50.5 (SD, 16.9) |
| Median | 51.0 (range, 5.0–87.0) |
| Sex | |
| Female | 185 (51.4%) |
| Male | 173 (48.1%) |
| Unknown | 2 (0.5%) |
| Joint inflammatory disease | |
| Spondyloarthropathies | 110 (30.6%) |
| RA | 89 (24.7%) |
| Osteoarthritis | 43 (11.9%) |
| Pigmented villonodular synovitis | 28 (7.8%) |
| Hemophilic arthropathy | 23 (6.4%) |
| Undifferentiated arthritis | 22 (6.1%) |
| Juvenile idiopathic arthritis | 19 (5.3%) |
| Other inflammatory arthritis | 15 (4.2%) |
| Recurrent joint effusion after surgery | 9 (2.5%) |
| Unknown | 2 (0.5%) |
| Concurrent medication | |
| nbDMARD | 323 (89.7%) |
| bDMARD | 21 (5.8%) |
| Unknown | 16 (4.5%) |
| Joint treated | |
| Knee | 324 (82.7%) |
| Ankle | 24 (6.1%) |
| Elbow | 18 (4.6%) |
| Wrist | 13 (3.3%) |
| Shoulder | 9 (2.3%) |
| Hip | 4 (1.0%) |
| Radiopharmaceutical | |
| [90Y]Y-citrate | 327 (83.4%) |
| [186Re]Re-sulfide | 39 (10.0%) |
| Unknown | 26 (6.6%) |
| Radiologic class of joint destruction | |
| 0 | 218 (55.6%) |
| 1 | 36 (9.2%) |
| 2 | 35 (8.9%) |
| 3 | 36 (9.2%) |
| Unknown | 67 (17.1%) |
nbDMARD = nonbiologic disease-modifying antirheumatic drug; bDMARD = biologic disease-modifying antirheumatic drug.
Data are number followed by percentage in parentheses, except for age. Total patients = 360, and total joints = 392.